0001104659-24-086535.txt : 20240807 0001104659-24-086535.hdr.sgml : 20240807 20240807071330 ACCESSION NUMBER: 0001104659-24-086535 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240807 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC CENTRAL INDEX KEY: 0001393434 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36554 FILM NUMBER: 241181411 BUSINESS ADDRESS: STREET 1: 15 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-357-4000 MAIL ADDRESS: STREET 1: 15 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: I-THERAPEUTIX INC DATE OF NAME CHANGE: 20070315 8-K 1 tm2420962d1_8k.htm FORM 8-K
false 0001393434 OCULAR THERAPEUTIX, INC 0001393434 2024-08-07 2024-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2024

 

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

 

Delaware   001-36554   20-5560161
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

15 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code: (781) 357-4000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.0001 par value per share   OCUL   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 7, 2024, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

99.1 Press Release of Ocular Therapeutix, Inc., dated August 7, 2024
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OCULAR THERAPEUTIX, INC.
     
Date: August 7, 2024 By: /s/ Donald Notman
    Donald Notman
    Chief Financial Officer

 

 

 EX-99.1 2 tm2420962d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Ocular Therapeutix™ Reports Second Quarter 2024 Results

 

SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial

 

Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients

 

Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028

 

Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET

 

BEDFORD, MA, August 7, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights, including an update on the Phase 3 AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) wet age-related macular degeneration (wet AMD) program.

 

“I am pleased to report that Ocular is making outstanding progress in 2024. Over the last six months, we have clarified our mission of becoming a leader in the treatment of retinal disease and thoughtfully assembled the team to deliver this mission. The exemplary work of our clinical team has allowed Ocular to accelerate enrollment in the SOL-1 superiority study of AXPAXLI in wet AMD and to swiftly design and initiate the SOL-R non-inferiority repeat dosing study. We are also pleased to report that the FDA has now confirmed that SOL-R is appropriate for use as our second registrational study,” said Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix. “In June, we held a successful Investor Day that allowed us to put SOL-1 and SOL-R into context as complementary studies, addressing questions on durability and repeat dosing. We believe this could put us in a strong position to target a favorable label for AXPAXLI in wet AMD, potentially providing desired flexibility for physicians. The Investor Day also provided us with an opportunity to review the durable and consistent data from the HELIOS study in non-proliferative diabetic retinopathy (NPDR). With these HELIOS data, plus data from our two prior clinical trials in wet AMD, we remain extremely enthusiastic about our SOL-1 and SOL-R registrational studies.”

 

Dr. Dugel concluded, “We believe this is just the beginning of a new age in retinal disease care, and we look forward to updating the investment community and our stakeholders on our progress.”

 

Recent Achievements and Upcoming Milestones:

 

·Initiated site activation and patient enrollment in SOL-R AXPAXLI repeat dosing registrational study (Phase 3, wet AMD). Multiple sites are now active with several subjects enrolled in this study designed to produce commercially meaningful data and which the U.S. Food and Drug Administration (FDA) has confirmed is appropriate for use as Ocular’s second adequate and well controlled study to support a potential New Drug Application (NDA). SOL-R compares AXPAXLI dosed every six months (Q6M) to the current standard of care, aflibercept (2 mg) dosed every eight weeks. A third arm evaluating 8 mg aflibercept dosed Q6M is incorporated to ensure adequate masking, in alignment with FDA guidance for non-inferiority studies. The study incorporates five aflibercept (2 mg) loading doses around two evaluation visits to exclude subjects with significant retinal fluid fluctuations, designed specifically for patient enrichment. The Company believes this patient enrichment design may improve the probability of success for the clinical trial by reducing patient variability. SOL-R aims to randomize approximately 825 subjects who are treatment naïve or have been diagnosed with wet AMD in the study eye within three months prior to enrollment.

 

 

 

 

·Patient enrollment accelerating in SOL-1 AXPAXLI registrational study (Phase 3, wet AMD). During its June Investor Day, the Company announced 60 active study sites, and 151 subjects enrolled in various stages of loading and randomization, as of June 7, 2024. Site activation and patient enrollment continue to accelerate in the superiority study comparing a single AXPAXLI implant to a single aflibercept (2 mg) injection, after both arms receive two aflibercept (2 mg) loading doses.

 

·Positive HELIOS 48-week data presented at June Investor Day and ASRS (Phase 1, NPDR). The 48-week HELIOS results showed that all signals of diabetic retinopathy severity scale (DRSS) improvement were observed in AXPAXLI-treated subjects while any vision threatening complications that developed in the study were in the sham-treated control group. In the Phase 1 study, AXPAXLI was administered without a loading dose of aflibercept and demonstrated DRSS stability or improvement with durable effect through 48 weeks and was generally well-tolerated, with no reported incidence of intraocular inflammation, iritis, vitritis or vasculitis, in subjects with NPDR. The impressive data were selected for a late-breaker presentation during the 42nd American Society of Retina Specialist (ASRS) Annual Scientific Meeting.

 

Second Quarter Ended June 30, 2024, Financial Results

 

Total cash and cash equivalents were $459.7 million as of June 30, 2024. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA®, the Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028.

 

Total net revenue was $16.4 million for the second quarter of 2024, an 8.3% increase over total net revenue of $15.2 million in the comparable period in 2023, driven by increased revenues from DEXTENZA sales. The Company expects full-year 2024 total net revenues for DEXTENZA to be between $62.0 million and $67.0 million, compared to $57.9 million reported in 2023. Total net revenue includes both gross DEXTENZA product revenue, net of discounts, rebates, and returns, which the Company refers to as net product revenue, and collaboration revenue.

 

Research and development expenses for the second quarter of 2024 were $28.9 million versus $15.1 million for the comparable period in 2023, reflecting an increase in overall clinical expenses associated with product development programs, specifically the ongoing enrollment in the SOL-1 Phase 3 clinical trial, and the design and initiation of start-up activities in the SOL-R Phase 3 clinical trial, as well as additional personnel and professional services to support these clinical trials.

 

 

 

 

Selling and marketing expenses were $10.0 million in the second quarter of 2024, as compared to $11.2 million for the comparable quarter of 2023, primarily reflecting a decrease in professional fees and stock compensation and other personnel costs.

 

General and administrative expenses were $19.7 million for the second quarter of 2024 versus $8.2 million in the comparable quarter of 2023, primarily due to an increase in one-time personnel-related costs, including stock-based compensation expense for certain employees who departed the Company, restructuring costs, and professional services, including legal expense.

 

Net loss for the second quarter of 2024 was $(43.8) million, or a net loss of $(0.26) per share on both a basic and diluted basis, compared to a net loss of $(20.7) million, or a net loss of $(0.26) per share on both a basic and diluted basis, for the comparable period in 2023. The net loss in the second quarter of 2024 included a $(3.0) million non-cash loss attributable to the changes in the fair value of the derivative liability associated with the Barings credit facility, as compared to a $1.1 million non-cash gain attributable solely to the change in the fair value of the derivative liability associated with the Company’s convertible notes for the comparable quarter in 2023.

 

Outstanding shares as of August 2, 2024, were approximately 155.9 million.

 

Conference Call and Webcast Information

 

Ocular Therapeutix will host a conference call and webcast today at 8:00 AM ET to discuss recent business progress and second quarter financial results. To access the call, please dial: 1 (800) 343-4136 (United States) or 1 (203) 518-9843 (International) and reference the conference ID “OCULAR”. To access the webcast, please click here. The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for 90 days.

 

About Ocular Therapeutix, Inc.

 

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

 

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

 

Follow the Company on its website, LinkedIn or X.

 

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

 

 

 

 

Forward-Looking Statements

 

Any statements in this press release about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company’s product candidates; the timing, design, and enrollment of the Company’s SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company’s plans to advance the development of AXPAXLI and its other product candidates; the potential utility of any of the Company’s product candidates; the Company’s objective to become a leader in retinal care; the Company’s guidance regarding its projected total net product revenues for DEXTENZA; the Company’s cash runway and the sufficiency of the Company’s cash resources; and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “goal”, “may”, “might”, “plan”, “predict”, “project”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of any product or product candidate that receives regulatory approval; the initiation, design, timing, conduct and outcomes of ongoing and planned clinical trials; the risk that the FDA will not agree with the Company’s interpretation of the written agreement under the Special Protocol Assessment for the SOL-1 trial; the risk that the FDA may not agree that the protocol and statistical analysis plan of SOL-R or the data generated by the SOL-1 and SOL-R trials support marketing approval; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial will be predictive of final data from such trial, or whether data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; availability of data from clinical trials and expectations for regulatory submissions and approvals; the Company’s scientific approach and general development progress; uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials; the Company’s existing indebtedness and the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; the Company’s ability to enter into strategic alliances or generate additional funding on a timely basis, on favorable terms, or at all; and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

 

Investors & Media

 

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations

bslattery@ocutx.com

 

 

 

 

Ocular Therapeutix, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

   June 30,   December 31, 
   2024   2023 
Assets          
Current assets:          
Cash and cash equivalents  $459,690   $195,807 
Accounts receivable, net   30,232    26,179 
Inventory   2,547    2,305 
Restricted cash   —    150 
Prepaid expenses and other current assets   6,116    7,794 
Total current assets   498,585    232,235 
Property and equipment, net   10,887    11,739 
Restricted cash   1,614    1,614 
Operating lease assets   6,005    6,472 
Total assets  $517,091   $252,060 
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $3,689   $4,389 
Accrued expenses and other current liabilities   24,358    28,666 
Deferred revenue   269    255 
Operating lease liabilities   1,656    1,586 
Total current liabilities   29,972    34,896 
Other liabilities:          
Operating lease liabilities, net of current portion   6,100    6,878 
Derivative liabilities   22,078    29,987 
Deferred revenue, net of current portion   14,000    14,135 
Notes payable, net   67,132    65,787 
Other non-current liabilities   114    108 
Convertible Notes, net   —    9,138 
Total liabilities   139,396    160,929 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at June 30, 2024 and December 31, 2023, respectively   —    — 
Common stock, $0.0001 par value; 400,000,000 shares and 200,000,000 shares authorized and 155,624,363 and 114,963,193 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively   16    12 
Additional paid-in capital   1,183,882    788,697 
Accumulated deficit   (806,203)   (697,578)
Total stockholders’ equity   377,695    91,131 
Total liabilities and stockholders’ equity  $517,091   $252,060 

 

 

 

 

Ocular Therapeutix, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
Revenue:                    
Product revenue, net  $16,379    15,029   $31,094   $28,243 
Collaboration revenue   62    157    121    318 
Total revenue, net   16,441    15,186    31,215    28,561 
Costs and operating expenses:                    
Cost of product revenue   1,509    1,304    2,835    2,517 
Research and development   28,857    15,094    49,592    29,842 
Selling and marketing   9,994    11,153    20,177    21,989 
General and administrative   19,671    8,205    33,818    17,332 
Total costs and operating expenses   60,031    35,756    106,422    71,680 
Loss from operations   (43,590)   (20,570)   (75,207)   (43,119)
Other income (expense):                    
Interest income   6,036    748    9,958    1,312 
Interest expense   (3,196)   (1,991)   (7,247)   (3,760)
Change in fair value of derivative liabilities   (3,027)   1,131    (8,179)   (5,432)
Loss on extinguishment of debt   —    —    (27,950)   — 
Other expense   —    —    —    (1)
Total other income (expense), net   (187)   (112)   (33,418)   (7,881)
Net loss  $(43,777)  $(20,682)  $(108,625)  $(51,000)
Net loss per share, basic  $(0.26)  $(0.26)  $(0.73)  $(0.66)
Weighted average common shares outstanding, basic   165,824,778    78,047,705    148,922,937    77,718,823 
Net loss per share, diluted  $(0.26)  $(0.26)  $(0.73)  $(0.66)
Weighted average common shares outstanding, diluted   165,824,778    78,047,705    148,922,937    77,718,823 

 

 

 

 EX-101.SCH 3 ocul-20240807.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ocul-20240807_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ocul-20240807_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2024
Entity File Number 001-36554
Entity Registrant Name OCULAR THERAPEUTIX, INC
Entity Central Index Key 0001393434
Entity Tax Identification Number 20-5560161
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 15 Crosby Drive
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code 781
Local Phone Number 357-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol OCUL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ocutx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ocul-20240807.xsd ocul-20240807_lab.xml ocul-20240807_pre.xml tm2420962d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420962d1_8k.htm": { "nsprefix": "ocul", "nsuri": "http://ocutx.com/20240807", "dts": { "schema": { "local": [ "ocul-20240807.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ocul-20240807_lab.xml" ] }, "presentationLink": { "local": [ "ocul-20240807_pre.xml" ] }, "inline": { "local": [ "tm2420962d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://ocutx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420962d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420962d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ocutx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-086535-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-086535-xbrl.zip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end XML 17 tm2420962d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001393434 2024-08-07 2024-08-07 iso4217:USD shares iso4217:USD shares false 0001393434 OCULAR THERAPEUTIX, INC 8-K 2024-08-07 DE 001-36554 20-5560161 15 Crosby Drive Bedford MA 01730 781 357-4000 false false false false Common Stock, $0.0001 par value per share OCUL NASDAQ false